Target $21
Wednesday, March 17, 2021
Vaccine eligibility expanding to all Iowans by April 5
Gov. Reynolds on Wednesday announced all Iowans will be eligible for COVID-19 vaccination starting on April 5, as long as the state’s vaccine dose allocation from the federal government increases as expected.
Reynolds said the federal vaccine allocations are expected to increase significantly by the week of March 29 to 20 million dose nationwide, which could include 4-6 million doses of the Johnson and Johnson vaccine. She did not explain how many would be allocated to Iowa.
The allocation is expected to increase again in April to more than 22 million doses nationwide.
The eligibility expansion is dependent on this significant increase in dose allocations from the federal government.
“Getting vaccinated is the most important thing that each of us can do to ensure that our state’s recovery from COVID-19 is both strong and sustainable,” Reynolds said. “We all want life to get back to normal, for our businesses to rebound, for our high school seniors to graduate together, our church communities to gather again fully in-person and our families to be reunited. All of these things are possible and soon, but like everything else over this past year, it will depend on all of us doing our part for the greater good.”
Reynolds encouraged Iowans to get vaccinated as soon as possible.
https://www.kcrg.com/2021/03/17/iowa-to-expand-vaccine-eligibility-to-everyone-by-april-5/
China Plans To Ask U.S. To Roll Back Trump Policies In Alaska Meet
CHINA PLANS TO ASK U.S. TO ROLL BACK TRUMP POLICIES IN ALASKA MEETING - WSJ
* CHINESE OFFICIALS PLAN TO PROPOSE RE-ESTABLISHING REGULAR HIGH-LEVEL MEETINGS BETWEEN CHINA AND U.S.- WSJ
* CHINESE OFFICIALS ALSO PLAN TO PROPOSE SCHEDULING VIRTUAL SUMMIT BETWEEN XI JINPING & BIDEN IN APRIL DURING GLOBAL CONFERENCE ON CLIMATE CHANGE- WSJ
* CHINA ALSO PLANS TO PROPOSE THAT BOTH COUNTRIES CREATE A "VACCINE PASSPORT" TO VERIFY PROOF OF IMMUNIZATION - WSJ Source text : https://on.wsj.com/3bWek99
Translate Bio Phase 1/2 cystic fibrosis trial interim data misses on lung function
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 --
-- Data supports advancing mRNA therapeutics for pulmonary diseases; additional translational research ongoing to optimize future clinical development of mRNA cystic fibrosis programs, including MRT5005 and a next-generation CF candidate --
-- Company committed to advancing innovative mRNA therapeutics for all patients with CF; Phase 1/2 clinical trial for MRT5005 ongoing and next-generation CF candidate anticipated to enter IND-enabling studies in 2H 2021 --
-- Conference call today at 4:30 pm ET --
Translate Bio will host a conference call and webcast today at 4:30 PM ET to discuss the second interim results from the single-ascending and multiple ascending dose portions of its Phase 1/2 clinical trial of MRT5005 in patients with CF. The live webcast can be accessed on the investor page of Translate Bio’s website at https://investors.translate.bio/investors/news-and-events. The conference call can be accessed by dialing (877) 377-8524 (toll-free domestic) or (629) 228-0742 (international) and using the conference ID 3383727. A replay of the webcast will be available on Translate Bio’s website approximately two hours after the completion of the event and will be archived for up to 30 days.
https://finance.yahoo.com/news/translate-bio-announces-results-second-200500790.html
U.S. plans to use real-world, trial data to judge when vaccines need update
U.S. officials plan to use data gathered from people who have already been vaccinated against COVID-19 as well as data from ongoing clinical trials to determine when and whether current vaccines need to be updated to address viral variants.
Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, said in a hearing on Wednesday that his agency has already started getting data on vaccine safety from surveillance systems.
Those systems have been set up to gather reports of vaccine side effects from individuals and physicians and are managed in partnership with the FDA and the U.S. Centers for Disease Control and Prevention.
The FDA is also working with the U.S. Centers for Medicare and Medicaid Services to mine data in health information systems to look for possible safety signals.
Marks told a hearing of the House Committee on Energy & Commerce that his agency has already begun to receive data on vaccine safety.
He said the FDA intends to use these surveillance systems to determine whether vaccines continue to be effective in the presence of new variants of the coronavirus, especially those that may be capable of evading protection from vaccines.
Marks told the panel he expects to start receiving data on whether vaccines are continuing to work within the next few months. He is also continuing to monitor clinical trials for signs of vaccine failure.
Large numbers of breakthrough infections in which vaccinated people get COVID-19 would suggest that booster shots - using the same or a retooled vaccine targeting specific variants - are needed.
Moderna Inc, Pfizer Inc and BioNTech SE, Johnson & Johnson and Novavax Inc have announced they have begun work on vaccines to address variants should they be needed.
94% of US seniors prescribed drugs that up risk of falling: study
Ninety-four percent of older Americans were prescribed a drug that increased their risk of falling in 2017, up from just 57 percent in 1999, according to a recent study published in Pharmacoepidemiology and Drug Safety.
The study used data on prescription fills among Americans 65 and older from the National Vital Statistics System and the Medical Expenditure Panel Survey.
The study also found that the rate of death caused by falls in older adults more than doubled from 1999 to 2017. The CDC says that nearly $50 billion is spent each year on medical costs related to fall injuries among older adults.
"Our study indicates two trends increasing concurrently at a population level that should be examined at the individual level," Amy Shaver, PhD, one of the study's authors, said in a March 17 new release. "Our hope is it will start more conversations on health care teams about the pros and cons of medications prescribed for vulnerable populations."
Drugs that increase the risk of falling include antidepressants, anticonvulsants, antipsychotics, antihypertensives, opioids, sedative hypnotics and benzodiazepines.
Okla. 1st state to cover opioid addiction drugs, therapy with Medicaid
The federal government has allowed Oklahoma's Medicaid program to cover drugs designed to treat opioid addiction, News 9, a CBS affiliate in Oklahoma, City, reported March 16.
Oklahoma is now the first state in which Medicaid is allowed to cover and reimburse drugs such as methadone and naltrexone, which are used to treat opioid use disorder. The state's Medicaid program can also cover opioid use disorder treatment services, such as counseling and behavior therapy, News 9 reported.
Oklahoma's deputy Medicaid director, Traylor Rains, told News 9 the change will help about 3,500 Oklahomans on Medicaid, and even more people after a Medicaid expansion in July.
Read the full article here.
Subscribe to:
Comments (Atom)